Collaboration and transparency in the development of cost-effectiveness models can increase the credibility and relevance of these models for local decision making, according to this JMCP article.
ICER's analysis of biologics used to treat asthma falls short of adequately addressing factors related to patients' health and quality of life, particularly those with severe, uncontrolled asthma, according to this JMCP article by the Asthma and Allergy Foundation of America's CEO.
A summary of an ICER cost-effectiveness analysis published in JMCP found that despite incremental clinical benefits, biologics used to treat asthma have low long-term value for money.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the updated draft industry guidance on “Nonproprietary Naming of Biological Products” published in the Federal Register on March 8, 2019. AMCP appreciates FDA’s ongoing efforts to issue and update guidance that allow health care providers to safely and effectively use biosimilar products.
May 2019 News & Views: Survey Identifies Barriers and Solutions to Biosimilar Adoption; In Memoriam: Past President Cathy Carroll; CEO Blog: PAs Play Key Role in Appropriate Medication Use; PGY1 Residents First to Rotate at AMCP/Foundation Headquarters